By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Platelet aggregation inhibitors > Caplacizumab > Caplacizumab Dosage
Platelet aggregation inhibitors
https://themeditary.com/dosage-information/caplacizumab-dosage-10939.html

Caplacizumab Dosage

Drug Detail:Caplacizumab (Caplacizumab [ kap-la-siz-ue-mab ])

Drug Class: Platelet aggregation inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura

Initial dose:

  • First day of treatment: 11 mg bolus IV injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on Day 1

Maintenance dose:
  • Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once a day following plasma exchange
  • Treatment after plasma exchange period: 11 mg subcutaneous injection once a day continuing for 30 days following the last daily plasma exchange. If after initial treatment course sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.

Comments:
  • Discontinue this drug if the patient experiences more than 2 recurrences of acquired thrombotic thrombocytopenic purpura (aTTP) during treatment with this drug.
  • Withhold this drug 7 days prior to elective surgery, dental procedures, or other invasive interventions.

Use: Treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Mild to moderate liver dysfunction: Data not available
Severe liver dysfunction: Caution recommended; monitor closely for bleeding

Precautions

CONTRAINDICATIONS:

  • Previous severe hypersensitivity reaction (e.g., urticaria) to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • The first dose should be administered by a healthcare provider as a bolus IV injection. Administer subsequent doses subcutaneously in the abdomen. Avoid injections around the navel. Do not administer consecutive injections in the same abdominal quadrant.
  • Patients or caregivers may inject this drug subcutaneously after proper training on the preparation and administration of this drug, including aseptic technique.
  • If a dose is missed during the plasma exchange period, it should be given as soon as possible.
  • If a dose is missed after the plasma exchange period, it can be administered within 12 hours of the scheduled time of administration. Beyond 12 hours, the missed dose should be skipped, and the next daily dose administered according to the usual dosing schedule.

Storage requirements:
  • Store refrigerated at 2C to 8C (36F to 46F) in the original carton to protect from light.
  • Do not freeze.
  • Unopened vials may be stored in the original carton at room temperature up to 30C (86F) for a single period of up to 2 months.
  • Do not return the drug to the refrigerator after it has been stored at room temperature.
  • Use the reconstituted solution immediately, if possible. Otherwise, use within 4 hours after reconstitution when stored in the refrigerator at 2C to 8C (36F to 46F).

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

Monitoring:
  • Cardiovascular: Bleeding

Patient advice:
  • Advise patients that bruising and bleeding may occur more easily and that it may take longer than usual to stop bleeding.
  • Advise patients to contact their healthcare provider immediately if excessive bruising or bleeding occurs.
  • Advise patients to inform their healthcare provider before scheduling any elective surgery, dental procedure, or other invasive intervention.


Monitoring:
  • Cardiovascular: Bleeding

Patient advice:
  • Advise patients that bruising and bleeding may occur more easily and that it may take longer than usual to stop bleeding.
  • Advise patients to contact their healthcare provider immediately if excessive bruising or bleeding occurs.
  • Advise patients to inform their healthcare provider before scheduling any elective surgery, dental procedure, or other invasive intervention.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by